Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of online get-togethers and deadlines has returned. And so has volatility in the markets, which reminds us of what happened the last time Chicken Little claimed the sky was falling. The rejoinder, of course, is ‘sell sky.’ Or maybe not. In any event, here are a few tidbits to keep you focused. We hope your day is productive and profitable. Meanwhile, do keep in touch. …

A key U.S. Senate panel is expanding its plans to punish drug makers that hike prices faster than inflation, according to an internal Senate document described to STAT. The policy, which is being considered as part of efforts by Democrats to include drug-pricing reforms in a sweeping government spending package, has the potential to change the way pharmaceutical companies set launch prices for their medicines, and how they choose to adjust prices over time.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment